Abstract
Abstract
Purpose
Vestibulotoxicity associated with cisplatin chemotherapy is known to exist, but the extent, severity, and impact is unclear from the literature. This study explored knowledge, experiences, and opinions of audiovestibular professionals about cisplatin vestibulotoxicity.
Methods
An online survey was disseminated to clinicians working in the audiovestibular field.
Results
Ninety-three respondents participated in the survey. Most professionals were aware of potential vestibulotoxicity associated with cisplatin chemotherapy. Thirty-three percent of the respondents reported that they had seen patients with cisplatin vestibulotoxicity. Forty percent of them were confident in making the diagnosis and in managing the patient in this situation. The prevalence and impact of vestibulotoxicity including practicality of the assessment should be considered when designing an effective vestibulotoxicity screening protocol.
Conclusion
This study provides a better understanding of cisplatin vestibulotoxicity from the perspectives of audiovestibular clinicians, which will underpin appropriate detection and management of the condition.
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Otorhinolaryngology
Reference32 articles.
1. Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, Dolan ME (2019) Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res 25(4):1147–1155. https://doi.org/10.1158/1078-0432.ccr-18-2244
2. Cianfrone G, Pentangelo D, Cianfrone F, Mazzei F, Turchetta R, Orlando MP, Altissimi G (2011) Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci 15(6):601–636
3. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB (2016) Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 34(23):2712–2720. https://doi.org/10.1200/JCO.2016.66.8822
4. van As JW, van den Berg H, van Dalen EC (2016) Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev 8:Cd010181. https://doi.org/10.1002/14651858.CD010181.pub2
5. Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG (2014) Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer 61(4):601–605. https://doi.org/10.1002/pbc.24830
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献